# Phase 1/2 leukemia trials recruiting: 148 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 148 trials in phase 1/2 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 leukemia trials: 148 rows for $7.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 148
- Recruiting or not yet: 148
- Read on: November 19, 2026

## Trials

The 25 newest of 148, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939971 | A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML | TuHURA Biosciences, Inc. | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939971) |
| November 9, 2026 | NCT07926607 | Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Second Affiliated Hospital of Nanchang University | Phase 1/2 | Not yet recruiting | Acute Myeloblastic Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926607) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 16, 2026 | NCT07877610 | CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1/2 | Recruiting | AML (Acute Myeloid Leukemia), BPDCN | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877610) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| September 29, 2026 | NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | Dana-Farber Cancer Institute | Phase 1/2 | Not yet recruiting | Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847957) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| August 12, 2026 | NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | Chaser Therapeutics, Inc. | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761533) |
| August 11, 2026 | NCT07757672 | Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | AML (Acute Myelogenous Leukemia, HSCT | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757672) |
| August 6, 2026 | NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | Vitruviae | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749976) |
| July 24, 2026 | NCT07726576 | Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia | University Hospital, Bordeaux | Phase 1/2 | Not yet recruiting | Leukemia, Myeloid, Acute | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726576) |
| July 23, 2026 | NCT07722312 | S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory... | Servier | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722312) |
| July 22, 2026 | NCT07719348 | A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | Servier | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719348) |
| June 23, 2026 | NCT07663864 | Luspatercept for CIA in AML | Guangdong Second Provincial General Hospital | Phase 1/2 | Recruiting | Chemotherapy-inducing Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663864) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 22, 2026 | NCT07604233 | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | M.D. Anderson Cancer Center | Phase 1/2 | Not yet recruiting | Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604233) |
| May 18, 2026 | NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | Masonic Cancer Center, University of Minnesota | Phase 1/2 | Recruiting | Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591649) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| April 16, 2026 | NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532824) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| April 9, 2026 | NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1/2 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520006) |
| March 20, 2026 | NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486726) |
| March 13, 2026 | NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients... | Gyala Therapeutics | Phase 1/2 | Recruiting | Acute Myeloblastic Leukaemia, Leukemia, T-Cell | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471789) |
| March 5, 2026 | NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | The First Affiliated Hospital of Soochow University | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451912) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 15 |
| Princess Maxima Center for Pediatric Oncology | 5 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 5 |
| Essen Biotech | 4 |
| National Cancer Institute (NCI) | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| Shenzhen Geno-Immune Medical Institute | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Fred Hutchinson Cancer Center | 3 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Servier | 2 |
| Nationwide Children's Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 2 |
| Xuzhou Medical University | 2 |
| Guangdong Second Provincial General Hospital | 1 |
| TuHURA Biosciences, Inc. | 1 |
| Ellipses Pharma | 1 |
| [AB Science](https://specstream.ai/data/clinical-trials/company/ab-science) | 1 |
| [Stemline Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/stemline-therapeutics-inc) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Sheba Medical Center | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Chordia Therapeutics, Inc. | 1 |
| Haukeland University Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 73 |
| China | 40 |
| France | 22 |
| Spain | 19 |
| Germany | 18 |
| United Kingdom | 16 |
| Italy | 16 |
| Australia | 15 |
| South Korea | 10 |
| Netherlands | 8 |
| Sweden | 8 |
| Canada | 8 |
| Japan | 7 |
| Belgium | 6 |
| Denmark | 6 |
| Israel | 5 |
| Norway | 5 |
| Switzerland | 4 |
| Brazil | 4 |
| Taiwan | 4 |
| New Zealand | 4 |
| Austria | 3 |
| Finland | 3 |
| Ireland | 3 |
| Czechia | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Restaurants in the United States](https://specstream.ai/data/businesses/restaurants/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Flooring contractors in the United States](https://specstream.ai/data/businesses/flooring-contractors/united-states)
